Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are widely used in Ireland to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The market for these drugs has been steadily growing in recent years, with an increasing number of patients seeking treatment for respiratory illnesses.
Customer preferences: Patients in Ireland prefer bronchodilator drugs that are effective in providing quick relief from respiratory symptoms. They also prefer drugs that have minimal side effects and are easy to use. As a result, there is a growing demand for combination bronchodilator drugs that offer both short and long-acting relief.
Trends in the market: The bronchodilator drugs market in Ireland is expected to continue to grow in the coming years, driven by an aging population and increasing prevalence of respiratory diseases. In addition, the market is expected to see a shift towards newer, more effective drugs that offer better symptom relief and have fewer side effects. There is also an increasing trend towards the use of combination bronchodilator drugs, which offer both short and long-acting relief.
Local special circumstances: Ireland has a high prevalence of respiratory diseases, with asthma affecting approximately 470,000 people in the country. This has led to a growing demand for bronchodilator drugs, particularly among older adults. In addition, the country has a well-developed healthcare system that provides access to a wide range of respiratory treatments, including bronchodilator drugs.
Underlying macroeconomic factors: The Irish economy has been growing steadily in recent years, with a strong focus on healthcare and pharmaceuticals. This has led to increased investment in research and development of new bronchodilator drugs, as well as increased access to these drugs for patients. In addition, the country has a highly educated population with a strong awareness of respiratory diseases and the importance of seeking treatment. This has helped to drive demand for bronchodilator drugs and other respiratory treatments.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
